ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: The introduction of tyrosine kinase inhibitors (TKI) for BCR/ABL in patients with chronic phase (CP) chronic myeloid leukemia (CML) resulted for the first time in regular disappearance of the malignant clone, restoration of normal life expectancy, and even treatment free remission.